Advanced Non-Small Cell Lung Cancer Clinical Trials

62 recruitingLast updated: June 17, 2026

There are 62 actively recruiting advanced non-small cell lung cancer clinical trials across 50 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1. Top locations include Guangzhou, Guangdong, China, Houston, Texas, United States, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


Advanced Non-Small Cell Lung Cancer Trials at a Glance

62 actively recruiting trials for advanced non-small cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 50 countries. The largest study group is Phase 2 with 26 trials, with the heaviest enrollment activity in Guangzhou, Houston, and Shanghai. Lead sponsors running advanced non-small cell lung cancer studies include National Cancer Institute (NCI), Fudan University, and Bayer.

Browse advanced non-small cell lung cancer trials by phase

Treatments under study

About Advanced Non-Small Cell Lung Cancer Clinical Trials

Looking for clinical trials for Advanced Non-Small Cell Lung Cancer? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Non-Small Cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Non-Small Cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 62 trials

Recruiting
Phase 3

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer444 enrolled285 locationsNCT06452277
Recruiting
Phase 1Phase 2

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

HER2 MutationAdvanced Non-Small Cell Lung CancerEGFR Mutation
Bayer400 enrolled94 locationsNCT05099172
Recruiting
Phase 3

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled74 locationsNCT07185997
Recruiting
Phase 2

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Squamous Cell CarcinomaAdvanced Non-Small Cell Lung CancerAdvanced NSCLC+2 more
National Cancer Institute (NCI)85 enrolled1 locationNCT02133196
Recruiting
Phase 2Phase 3

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.626 enrolled770 locationsNCT04613596
Recruiting
Phase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled346 locationsNCT07222566
Recruiting
Phase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Hepatocellular CarcinomaLocally Advanced MelanomaMetastatic Hepatocellular Carcinoma+7 more
National Cancer Institute (NCI)30 enrolled1 locationNCT06066138
Recruiting
Phase 2

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung CancerNSCLCAdvanced Non-Small Cell Lung Cancer+1 more
Virginia Commonwealth University40 enrolled2 locationsNCT06731413
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Non-small Cell Lung CancerNSCLCNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Revolution Medicines, Inc.590 enrolled143 locationsNCT06881784
Recruiting
Phase 1

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Head and Neck CancerHNSCCColo-rectal Cancer+4 more
ALX Oncology Inc.170 enrolled8 locationsNCT07085091
Recruiting
Phase 1Phase 2

A 2-part Phase 1/2 Open-label Trial on ODM-212

Pancreatic CancerMesotheliomaNSCLC (Advanced Non-small Cell Lung Cancer)
Orion Corporation, Orion Pharma229 enrolled2 locationsNCT07563738
Recruiting
Phase 2

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center30 enrolled1 locationNCT07415005
Recruiting
Phase 2

Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

Locally Advanced Non-Small Cell Lung CancerStage IIIb Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung Cancer
Yang Hong28 enrolled1 locationNCT07309952
Recruiting
Phase 1Phase 2

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics266 enrolled41 locationsNCT06706076
Recruiting
Phase 1Phase 2

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.324 enrolled2 locationsNCT05482568
Recruiting
Phase 2

Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)

NSCLC (Advanced Non-small Cell Lung Cancer)EGFRMyelosuppression
The First Affiliated Hospital of Xiamen University49 enrolled1 locationNCT06992739
Recruiting
Phase 1

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)23 enrolled1 locationNCT05777603
Recruiting
Phase 2

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital20 enrolled1 locationNCT07528274
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Esophageal CancerPancreatic CancerUrothelial Carcinoma+10 more
Pfizer310 enrolled28 locationsNCT07090499
Recruiting
Not Applicable

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Leptomeningeal MetastasisNSCLC (Advanced Non-small Cell Lung Cancer)EGFR Activating Mutation+1 more
Guangzhou University of Traditional Chinese Medicine42 enrolled1 locationNCT07348965